{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:44:36Z","timestamp":1793051076760,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2024ZZBS10"],"award-info":[{"award-number":["2024ZZBS10"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["T2188102"],"award-info":[{"award-number":["T2188102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3405100"],"award-info":[{"award-number":["2023YFC3405100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LDQ23B050001"],"award-info":[{"award-number":["LDQ23B050001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LDQ24B020002"],"award-info":[{"award-number":["LDQ24B020002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xcrm.2026.103005","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:46:41Z","timestamp":1788274001000},"page":"103005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy"],"prefix":"10.1016","volume":"7","author":[{"given":"Yuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruonan","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghou","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8066-1524","authenticated-orcid":false,"given":"Weihong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103005_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jclinpath-2015-203050","article-title":"Gene of the month: MET","volume":"68","author":"Skead","year":"2015","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.xcrm.2026.103005_bib2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.103005_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-015-0547-6","article-title":"The clinical and functional significance of c-Met in breast cancer: a review","volume":"17","author":"Ho-Yen","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103005_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrclinonc.2017.40","article-title":"Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges","volume":"14","author":"Bradley","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103005_bib5","doi-asserted-by":"crossref","first-page":"532.e15","DOI":"10.1016\/j.urolonc.2017.03.027","article-title":"The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review","volume":"35","author":"Chen","year":"2017","journal-title":"Urol. Oncol.: Seminars and Original Investigations"},{"key":"10.1016\/j.xcrm.2026.103005_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.29496","article-title":"Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma","volume":"67","author":"Bouattour","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.xcrm.2026.103005_bib7","doi-asserted-by":"crossref","first-page":"9170","DOI":"10.3390\/ijms21239170","article-title":"Targeting HGF\/c-MET Axis in Pancreatic Cancer","volume":"21","author":"Pothula","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.103005_bib8","first-page":"83","article-title":"Prognostic and predictive value of MET deregulation in non-small cell lung cancer","volume":"3","author":"Finocchiaro","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103005_bib9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1535-7163.MCT-16-0472","article-title":"MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale","volume":"16","author":"Salgia","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.103005_bib10","first-page":"197","article-title":"High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients","volume":"27","author":"Park","year":"2012","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.xcrm.2026.103005_bib11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.103005_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jtho.2023.06.020","article-title":"MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition","volume":"19","author":"Riedel","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.103005_bib13","doi-asserted-by":"crossref","first-page":"10119","DOI":"10.3390\/ijms241210119","article-title":"Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?","volume":"24","author":"Spagnolo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.103005_bib14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.prp.2016.05.006","article-title":"Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis","volume":"212","author":"Pyo","year":"2016","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.xcrm.2026.103005_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.xcrm.2026.103005_bib16","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.103005_bib17","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","article-title":"Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"31","author":"Spigel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103005_bib18","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-06-2969","article-title":"AMG 102, a fully human anti-hepatocyte growth factor\/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts","volume":"13","author":"Jun","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103005_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in Lung Cancer: Will Expectations Finally Be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.103005_bib20","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s13346-024-01564-3","article-title":"Progress of antibody-drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies","volume":"14","author":"Mer","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.xcrm.2026.103005_bib21","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","article-title":"A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3","volume":"17","author":"Liu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103005_bib22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.annonc.2020.03.293","article-title":"Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial","volume":"31","author":"Schuler","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103005_bib23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103005_bib24","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","article-title":"Savolitinib: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2026.103005_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103005_bib26","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103005_bib27","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.103005_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.trecan.2017.11.009","article-title":"Have Clinical Trials Properly Assessed c-Met Inhibitors?","volume":"4","author":"Hughes","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.103005_bib29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/13543784.2018.1462336","article-title":"C-MET inhibitors for advanced non-small cell lung cancer","volume":"27","author":"Pasquini","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.xcrm.2026.103005_bib30","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41401-018-0198-0","article-title":"SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models","volume":"40","author":"Yang","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.xcrm.2026.103005_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/1878-0261.12600","article-title":"TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors","volume":"14","author":"Gymnopoulos","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103005_bib32","doi-asserted-by":"crossref","first-page":"25798","DOI":"10.1021\/acsomega.0c03102","article-title":"cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody-Drug Conjugate Targeting c-Met Overexpression Tumors","volume":"5","author":"Min","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.xcrm.2026.103005_bib33","article-title":"A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer","volume":"11","author":"Jin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.103005_bib34","first-page":"2100","article-title":"A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer. Clin","volume":"27","author":"Cazes","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103005_bib35","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1535-7163.MCT-21-0009","article-title":"A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade","volume":"20","author":"DaSilva","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.103005_bib36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103005_bib37","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40265-025-02210-z","article-title":"Telisotuzumab Vedotin: First Approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2026.103005_bib38","first-page":"33","article-title":"Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy","volume":"13","author":"Cruz","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.xcrm.2026.103005_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215969","article-title":"Drug conjugate-based anticancer therapy - Current status and perspectives","volume":"552","author":"Yang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2026.103005_bib40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12272-023-01447-0","article-title":"Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities","volume":"46","author":"Maiti","year":"2023","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.xcrm.2026.103005_bib41","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1248\/cpb.c21-00258","article-title":"Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates","volume":"69","author":"Matsuda","year":"2021","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.xcrm.2026.103005_bib42","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103005_bib43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/bc400439x","article-title":"Auristatin antibody drug conjugate physical instability and the role of drug payload","volume":"25","author":"Adem","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.xcrm.2026.103005_bib44","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311565120","article-title":"In pursuit of degenerative brain disease diagnosis: Dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor","volume":"120","author":"Bodily","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103005_bib45","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1021\/acs.analchem.2c00035","article-title":"Aptapaper\u2500An Aptamer-Functionalized Glass Fiber Paper Platform for Rapid Upconcentration and Detection of Small Molecules","volume":"94","author":"Mart\u00ednez-Jarqu\u00edn","year":"2022","journal-title":"Anal. Chem."},{"key":"10.1016\/j.xcrm.2026.103005_bib46","doi-asserted-by":"crossref","first-page":"17330","DOI":"10.1021\/acsami.1c01822","article-title":"Aptamer-Integrated Multianalyte-Detecting Paper Electrochemical Device","volume":"13","author":"Liu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.xcrm.2026.103005_bib47","doi-asserted-by":"crossref","first-page":"16442","DOI":"10.1021\/jacs.7b07799","article-title":"Micellar Thrombin-Binding Aptamers: Reversible Nanoscale Anticoagulants","volume":"139","author":"Roloff","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.103005_bib48","doi-asserted-by":"crossref","first-page":"21541","DOI":"10.1021\/jacs.1c08226","article-title":"Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape","volume":"143","author":"Sun","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.103005_bib49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","article-title":"Aptamers as Therapeutics","volume":"57","author":"Nimjee","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.xcrm.2026.103005_bib50","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1021\/acscentsci.4c00563","article-title":"Delivering DNA Aptamers Across the Blood-Brain Barrier Reveals Heterogeneous Decreased ATP in Different Brain Regions of Alzheimer's Disease Mouse Models","volume":"10","author":"Banik","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.xcrm.2026.103005_bib51","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1093\/nar\/gkac368","article-title":"Inert Pepper aptamer-mediated endogenous mRNA recognition and imaging in living cells","volume":"50","author":"Wang","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103005_bib52","doi-asserted-by":"crossref","first-page":"21441","DOI":"10.1002\/anie.202107250","article-title":"A Color-Shifting Near-Infrared Fluorescent Aptamer-Fluorophore Module for Live-Cell RNA Imaging","volume":"60","author":"Zhang","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.xcrm.2026.103005_bib53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1166\/jbn.2020.2943","article-title":"Advances in Aptamer Screening and Drug Delivery","volume":"16","author":"Tang","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.xcrm.2026.103005_bib54","doi-asserted-by":"crossref","first-page":"14473","DOI":"10.1039\/D1SC04229G","article-title":"Aptamer-modified DNA tetrahedra-gated metal-organic framework nanoparticle carriers for enhanced chemotherapy or photodynamic therapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.xcrm.2026.103005_bib55","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41392-024-01973-3","article-title":"Aptamer-drug conjugates-loaded bacteria for pancreatic cancer synergistic therapy","volume":"9","author":"Xiao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.103005_bib56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biomaterials.2018.08.021","article-title":"A basic insight into aptamer-drug conjugates (ApDCs)","volume":"182","author":"Xuan","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.xcrm.2026.103005_bib57","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103005_bib58","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","article-title":"Recent progress of aptamer\u2012drug conjugates in cancer therapy","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xcrm.2026.103005_bib59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2018.04.007","article-title":"Aptamer chemistry","volume":"134","author":"R\u00f6thlisberger","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2026.103005_bib60","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41467-017-01565-6","article-title":"A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer","volume":"8","author":"Li","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103005_bib61","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/jacs.9b10510","article-title":"Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer","volume":"142","author":"He","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.103005_bib62","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1021\/jacs.9b12409","article-title":"Conjugating Aptamer and Mitomycin C with Reductant-Responsive Linker Leading to Synergistically Enhanced Anticancer Effect","volume":"142","author":"Yang","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.103005_bib63","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1021\/acs.bioconjchem.0c00250","article-title":"Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy","volume":"31","author":"Tan","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.xcrm.2026.103005_bib64","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1021\/jacs.1c03013","article-title":"Regulating the Anticancer Efficacy of Sgc8-Combretastatin A4 Conjugates: A Case of Recognizing the Significance of Linker Chemistry for the Design of Aptamer-Based Targeted Drug Delivery Strategies","volume":"143","author":"Huang","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.103005_bib65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.omtn.2016.11.008","article-title":"Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth","volume":"6","author":"Yoon","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103005_bib66","doi-asserted-by":"crossref","first-page":"13131","DOI":"10.1039\/C4CC06016D","article-title":"A DNA aptamer to c-Met inhibits cancer cell migration","volume":"50","author":"Ueki","year":"2014","journal-title":"Chem. Commun. (Camb)"},{"key":"10.1016\/j.xcrm.2026.103005_bib67","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103005_bib68","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.xcrm.2026.103005_bib69","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1535-7163.MCT-16-0431","article-title":"RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models","volume":"15","author":"Strop","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.103005_bib70","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","article-title":"Receptor-ligand interactions for optimized endocytosis in targeted therapies","volume":"380","author":"Sung","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.xcrm.2026.103005_bib71","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro","volume":"94","author":"Lesche","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2026.103005_bib72","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.7150\/jca.86531","article-title":"The Role of Cathepsin B in Pathophysiologies of Non-tumor and Tumor tissues: A Systematic Review","volume":"14","author":"Wang","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.xcrm.2026.103005_bib73","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.omtn.2017.11.013","article-title":"Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers","volume":"10","author":"Kratschmer","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103005_bib74","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1073\/pnas.1717705115","article-title":"Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer","volume":"115","author":"Powell Gray","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103005_bib75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acsami.1c13980","article-title":"CD71-Specific Aptamer Conjugated with Monomethyl Auristatin E for the Treatment of Uveal Melanoma","volume":"14","author":"Zhang","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.xcrm.2026.103005_bib76","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.103005_bib77","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41392-025-02399-1","article-title":"An aptamer-drug conjugate for promising cancer therapy with comprehensive evaluation from rodents to non-human primates","volume":"10","author":"Su","year":"2025","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:14:46Z","timestamp":1789503286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126004222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666379126004222"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103005","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103005"}}